NasdaqCM - Delayed Quote • USD
RenovoRx, Inc. (RNXT)
At close: May 28 at 4:00 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Ramtin Agah M.D. | Founder, Chairman of Board & Chief Medical Officer | 332.89k | -- | 1966 |
| Mr. Shaun R. Bagai | CEO, Secretary & Director | 589.38k | -- | 1977 |
| Mr. Ronald B. Kocak CPA, CGMA | VP, Controller & Principal Accounting Officer | -- | -- | 1957 |
| Ms. Leesa Gentry | Chief Clinical Officer | -- | -- | 1970 |
RenovoRx, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 10
Description
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Corporate Governance
RenovoRx, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
August 15, 2024 at 12:30 PM UTC - August 19, 2024 at 12:30 PM UTC
RenovoRx, Inc. Earnings Date
Recent Events
Related Tickers
VRPX Virpax Pharmaceuticals, Inc.
0.7110
-0.43%
VRAX Virax Biolabs Group Limited
0.8900
-1.11%
INDP Indaptus Therapeutics, Inc.
2.4600
+5.58%
XBIO Xenetic Biosciences, Inc.
3.8200
-4.50%
KPRX Kiora Pharmaceuticals, Inc.
0.5335
-2.82%
PHGE BiomX Inc.
0.3601
+5.91%
REVB Revelation Biosciences, Inc.
1.7300
-5.98%
KTTA Pasithea Therapeutics Corp.
6.30
-2.32%
ENTX Entera Bio Ltd.
2.2500
-3.02%
CGTX Cognition Therapeutics, Inc.
2.2000
-13.73%